AVXS AveXis, Inc.

59.15
-0.21  -0.35%
Previous Close 59.36
Open 59.22
Price To book 6.14
Market Cap 1.64B
Shares 27,676,000
Volume 376,603
Short Ratio 14.74
Av. Daily Volume 519,595

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 ongoing. Data due 1Q 2017. Pivotal European trial initiation announced February 6, 2017. US trial to be initiated 1H 2017.
AVXS-101
Spinal muscular atrophy (SMA) Type 1

Latest News

  1. 3 Stocks Setting Up for Major Breakouts
  2. AveXis Appoints Rick Modi as Senior Vice President and Chief Business Officer
  3. Chardan Analyst Suggests An AveXis-Ionis Pair Trade
  4. AVEXIS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  5. AveXis Announces Single-Arm Design for European Pivotal Study of AVXS-101 in SMA Type 1 Patients
  6. AveXis Gene Therapy AVXS-101 Granted Access into EMA PRIME Program for Spinal Muscular Atrophy Type 1
  7. Hurry! These 5 Stocks Are About to Break Out Explosively
  8. AVEXIS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
  9. AveXis to Present at the 35th Annual J.P. Morgan Healthcare Conference
  10. Top Analyst Upgrades and Downgrades: Biogen, Comerica, Deere, NVIDIA, 21st Century Fox and More
  11. Avexis Inc. (AVXS): RA Capital Management Ups Its Stake
  12. AveXis to Use Intended Commercial GMP Product in SMA Type 2 Study
  13. AVEXIS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  14. AveXis to Use Intended Commercial GMP Product in SMA Type 2 Study
  15. 3 Reasons Biogen Inc. Stock Is Set to Soar in 2017
  16. Citron Research On AveXis: This Will Be One Of 2017's Biotech Blowups
  17. Do Hedge Funds Love ClubCorp Holdings Inc (MYCC)?
  18. 3 Things You Need to Know About Ionis Pharmaceuticals' Pipeline
  19. AVEXIS, INC. Financials